Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 3
Submit an article Journal homepage
293
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine

Akira ChibaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
,
Fumihiko NakamuraDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
,
Kumi NakazakiDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
&
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, JapanCorrespondence[email protected]
Pages 749-751 | Received 27 Feb 2017, Accepted 20 Jun 2017, Published online: 12 Jul 2017

References

  • Rummel MJ, Al-Batran SE, Kim S-Z, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. JCO. 2005;23:3383–3389.
  • Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4473–4479.
  • Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106–114.
  • Han XY. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer. J Clin Microbiol. 2007;45:1126–1132.
  • Hosoda T, Yokoyama A, Yoneda M, et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma. 2013;54:1327–1328.
  • Mitsumori T, Sueki Y, Kawashima I, et al. Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy. Rinsho Ketsueki. 2014;55:239–243.
  • Hasegawa T, Aisa Y, Shimazaki K, et al. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma. Ann Hematol. 2015;94:515–517.
  • Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–1097.
  • Kanda Y. Investigation of the freely available easy-to-use software “‘EZR’ for medical statistics”. Bone Marrow Transplant. 2013;48:452–458.
  • Tay MRJ, Lim ST, Tao M, et al. Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy. Leuk Lymphoma. 2014;55:182–187.
  • Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–5719.
  • Isono N, Imai Y, Watanabe A, et al. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leuk Lymphoma. 2016;57:2204–2207.
  • Mélet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013;65:2783–2790.
  • Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36:813–819.
  • Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:431–434.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.